<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37093522</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-190X</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</Title><ISOAbbreviation>BioDrugs</ISOAbbreviation></Journal><ArticleTitle>Lupus Nephritis: New and Emerging Biologic and Targeted Therapies.</ArticleTitle><Pagination><StartPage>463</StartPage><EndPage>475</EndPage><MedlinePgn>463-475</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40259-023-00597-3</ELocationID><Abstract><AbstractText>Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), a polyclonal systemic autoimmunity directed against nuclear and other self-antigens. SLE/LN affects mostly females during childbearing age, which puts them at risk for the progression of chronic kidney disease (CKD), cardiovascular disease, and pregnancy complications. The current management of LN involves the use of drugs with significant toxicities, and despite many attempts at novel drug interventions, the overall treatment efficacy has remained low. In this article, we discuss recent drug approvals and the upcoming pipeline of novel medications tested in clinical trials to improve effectiveness in terms of LN disease activity, LN relapse, and progression of LN-related CKD. In this context, we discuss (1) drugs with the potential to achieve these treatment goals by modulating SLE activity as the driving force for LN (e.g., belimumab, obinutuzumab, anifrolumab, and others); (2) drugs with SLE-non specific renoprotective effects by targeting non-immune mechanisms of LN progression (dapagliflozin, empagliflozin); and (3) drugs with dual immunosuppressive and antiproteinuric effects (voclosporin). Increasing the number of possible drug options will help to improve the management of LN in terms of efficacy and safety, and enable a more personalized treatment approach.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kale</LastName><ForeName>Ajinath</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Pharmacology, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Pilani, Rajasthan, 333 031, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lech</LastName><ForeName>Maciej</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine IV, Hospital of the Ludwig Maximilians University Munich, 80336, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anders</LastName><ForeName>Hans-Joachim</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine IV, Hospital of the Ludwig Maximilians University Munich, 80336, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaikwad</LastName><ForeName>Anil Bhanudas</ForeName><Initials>AB</Initials><Identifier Source="ORCID">0000-0003-4627-5504</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Pharmacology, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Pilani, Rajasthan, 333 031, India. anil.gaikwad@pilani.bits-pilani.ac.in.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AN372/29-1</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country/></Grant><Grant><GrantID>30-1</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>BioDrugs</MedlineTA><NlmUniqueID>9705305</NlmUniqueID><ISSNLinking>1173-8804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001688">Biological Products</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001688" MajorTopicYN="Y">Biological Products</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>24</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>24</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37093522</ArticleId><ArticleId IdType="doi">10.1007/s40259-023-00597-3</ArticleId><ArticleId IdType="pii">10.1007/s40259-023-00597-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anders HJ, et al. Lupus nephritis. Nat Rev Dis Prim. 2020;6(1):7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31974366</ArticleId><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema IM, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">29459092</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiger S, et al. Secondary immunodeficiency related to kidney disease (SIDKD)-definition, unmet need, and mechanisms. J Am Soc Nephrol. 2022;33(2):259&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">34907031</ArticleId><ArticleId IdType="pmc">8819985</ArticleId><ArticleId IdType="doi">10.1681/ASN.2021091257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int Suppl. 2021;100(45):S1&#x2013;276.</Citation></Reference><Reference><Citation>Fanouriakis A, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">32220834</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Arias AA, et al. The influence of repeated flares in response to therapy and prognosis in lupus nephritis. Nephrol Dial Transplant. 2022. 38(4):884-893.</Citation></Reference><Reference><Citation>Ponticelli C, Glassock RJ, Moroni G. Induction and maintenance therapy in proliferative lupus nephritis. J Nephrol. 2010;23(1):9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">20091481</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Lei Y, Rovin BH. Induction and maintenance therapy of lupus nephritis: an obituary. Kidney Int. 2021;99(2):288&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">33509346</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2020.11.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Rovin B. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int. 2016;90(3):493&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">27378475</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2016.05.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther. 2012;14(Suppl 4):S4.</Citation><ArticleIdList><ArticleId IdType="pubmed">23281889</ArticleId><ArticleId IdType="pmc">3535719</ArticleId><ArticleId IdType="doi">10.1186/ar3919</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul A, et al. Systemic lupus erythematosus. Nat Rev Dis Prim. 2016;2:16039.</Citation><ArticleIdList><ArticleId IdType="pubmed">27306639</ArticleId><ArticleId IdType="doi">10.1038/nrdp.2016.39</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulielmos GN, et al. The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry. Gene. 2018;668:59&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">29775752</ArticleId><ArticleId IdType="doi">10.1016/j.gene.2018.05.041</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31383717</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2018-214819</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer BF, et al. Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci. 2005;1050:124&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">16014527</ArticleId><ArticleId IdType="doi">10.1196/annals.1313.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Song D, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15(1):R12.</Citation><ArticleIdList><ArticleId IdType="pubmed">23320601</ArticleId><ArticleId IdType="pmc">3672792</ArticleId><ArticleId IdType="doi">10.1186/ar4142</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorraji SE, et al. Kidney tertiary lymphoid structures in lupus nephritis develop into large interconnected networks and resemble lymph nodes in gene signature. Am J Pathol. 2020;190(11):2203&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">32818496</ArticleId><ArticleId IdType="doi">10.1016/j.ajpath.2020.07.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Luyckx VA, et al. Nephron overload as a therapeutic target to maximize kidney lifespan. Nat Rev Nephrol. 2022;18(3):171&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">34880459</ArticleId><ArticleId IdType="doi">10.1038/s41581-021-00510-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Peired AJ, Romagnani P. SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, &#x201c;diabetic nephropathy&#x201d;, IgA nephropathy and podocytopathies with FSGS lesions. Nephrol Dial Transplant. 2022;37(9):1609&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">33313878</ArticleId><ArticleId IdType="doi">10.1093/ndt/gfaa329</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise LM, Stohl W. Belimumab and rituximab in systemic lupus erythematosus: a tale of two B cell-targeting agents. Front Med (Lausanne). 2020;7:303.</Citation><ArticleIdList><ArticleId IdType="pubmed">32695790</ArticleId><ArticleId IdType="pmc">7338653</ArticleId><ArticleId IdType="doi">10.3389/fmed.2020.00303</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy RA, et al. 10 Years of belimumab experience: what have we learnt? Lupus. 2021;30(11):1705&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">34238087</ArticleId><ArticleId IdType="pmc">8564244</ArticleId><ArticleId IdType="doi">10.1177/09612033211028653</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101(2):403&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">34560137</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2021.08.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Y, Loutan J, Anders HJ. B-cell depletion or belimumab or voclosporin for lupus nephritis? Curr Opin Nephrol Hypertens. 2021;30(2):237&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">33186226</ArticleId><ArticleId IdType="doi">10.1097/MNH.0000000000000662</ArticleId></ArticleIdList></Reference><Reference><Citation>US FDA. BENLYSTA (belimumab). 2017. http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761043lbl.pdf . Accessed 15 March 2023</Citation></Reference><Reference><Citation>Fabris M, et al. High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients. J Autoimmun. 2022;129: 102827.</Citation><ArticleIdList><ArticleId IdType="pubmed">35427999</ArticleId><ArticleId IdType="pmc">8995326</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2022.102827</ArticleId></ArticleIdList></Reference><Reference><Citation>Azoicai T, et al. Belimumab and antipneumococcal vaccination in patients with systemic lupus erythematosus. Expert Rev Clin Immunol. 2018;14(3):175&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29336179</ArticleId><ArticleId IdType="doi">10.1080/1744666X.2018.1429269</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlasova G, Mraz M. The regulation and function of CD20: an &#x201c;enigma&#x201d; of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">32482755</ArticleId><ArticleId IdType="pmc">7271567</ArticleId><ArticleId IdType="doi">10.3324/haematol.2019.243543</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrada AA, et al. Innate immune cells' contribution to systemic lupus erythematosus. Front Immunol. 2019;10.</Citation></Reference><Reference><Citation>Marinov AD, et al. The type II anti-CD20 antibody obinutuzumab (GA101) is more effective than rituximab at depleting B cells and treating disease in a murine lupus model. 2021;73(5):826&#x2013;36.</Citation></Reference><Reference><Citation>Furie RA, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">34615636</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2021-220920</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">31851795</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks ED. Anifrolumab: first approval. Drugs. 2021;81(15):1795&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">34554438</ArticleId><ArticleId IdType="doi">10.1007/s40265-021-01604-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne D, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81(4):496&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">35144924</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2021-221478</ArticleId></ArticleIdList></Reference><Reference><Citation>Fala L. Cosentyx (Secukinumab): first IL-17A antagonist receives FDA approval for moderate-to-severe plaque psoriasis. Am Health Drug Benef. 2016;9(Spec Feature):60&#x2013;3.</Citation></Reference><Reference><Citation>Chatzimichail G, Zillikens D, Tha&#xe7;i D. Secukinumab-induced chronic discoid lupus erythematosus. JAAD Case Rep. 2020;6(4):362&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">32258323</ArticleId><ArticleId IdType="pmc">7109566</ArticleId><ArticleId IdType="doi">10.1016/j.jdcr.2020.02.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C-Y, Tsai T-F. Aggravation of discoid lupus erythematosus in a patient with psoriasis and psoriatic arthritis during treatment of secukinumab: a case report and review of literature. Lupus. 2022;31(7):891&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">35438595</ArticleId><ArticleId IdType="doi">10.1177/09612033221095692</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa R, et al. Secukinumab on refractory lupus nephritis. Cureus. 2021;13(8): e17198.</Citation><ArticleIdList><ArticleId IdType="pubmed">34540426</ArticleId><ArticleId IdType="pmc">8439396</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh Y, et al. A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab. Lupus. 2018;27(7):1202&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29523055</ArticleId><ArticleId IdType="doi">10.1177/0961203318762598</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang J, et al. Review of secukinumab-induced adverse events of special interest and its potential pathogenesis. Dermatol Ther. 2022;35(8): e15599.</Citation><ArticleIdList><ArticleId IdType="pubmed">35614844</ArticleId><ArticleId IdType="doi">10.1111/dth.15599</ArticleId></ArticleIdList></Reference><Reference><Citation>Samy E, et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36(1):3&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">28215100</ArticleId><ArticleId IdType="doi">10.1080/08830185.2016.1276903</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaegi C, et al. Systematic review of safety and efficacy of atacicept in treating immune-mediated disorders. Front Immunol. 2020;11:433.</Citation><ArticleIdList><ArticleId IdType="pubmed">32265917</ArticleId><ArticleId IdType="pmc">7105675</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2020.00433</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginzler EM, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012;14(1):R33.</Citation><ArticleIdList><ArticleId IdType="pubmed">22325903</ArticleId><ArticleId IdType="pmc">3392829</ArticleId><ArticleId IdType="doi">10.1186/ar3738</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotyla P, Gumkowska-Sroka O, Wnuk B. Jak inhibitors for treatment of autoimmune diseases: lessons from systemic sclerosis and systemic lupus erythematosus. 2022;15(8):936.</Citation></Reference><Reference><Citation>Harrison C, Vannucchi AM. Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Ther Adv Hematol. 2012;3(6):341&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">23606937</ArticleId><ArticleId IdType="pmc">3627327</ArticleId><ArticleId IdType="doi">10.1177/2040620712459746</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, et al. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">34987201</ArticleId><ArticleId IdType="pmc">8730299</ArticleId><ArticleId IdType="doi">10.1038/s41584-021-00726-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripoll &#xc8;, et al. JAK3-STAT pathway blocking benefits in experimental lupus nephritis. Arthritis Res Ther. 2016;18(1):134.</Citation><ArticleIdList><ArticleId IdType="pubmed">27278657</ArticleId><ArticleId IdType="pmc">4898357</ArticleId><ArticleId IdType="doi">10.1186/s13075-016-1034-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q, et al. Tofacitinib ameliorates lupus through suppression of T cell activation mediated by TGF-beta type I receptor. Front Immunol. 2021;12: 675542.</Citation><ArticleIdList><ArticleId IdType="pubmed">34394075</ArticleId><ArticleId IdType="pmc">8358742</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.675542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasni SA, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391.</Citation><ArticleIdList><ArticleId IdType="pubmed">34099646</ArticleId><ArticleId IdType="pmc">8185103</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-23361-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, et al. Baricitinib attenuates autoimmune phenotype and podocyte injury in a murine model of systemic lupus erythematosus. Front Immunol. 2021;12: 704526.</Citation><ArticleIdList><ArticleId IdType="pubmed">34497607</ArticleId><ArticleId IdType="pmc">8419414</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.704526</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Y, et al. A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas(lpr) mice with proliferative lupus nephritis predicts low effect size. Kidney Int. 2021;99(6):1331&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">33607177</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2021.01.024</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T, et al. Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Ann Rheum Dis. 2022;81(9):1267&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">35609978</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2022-222335</ArticleId></ArticleIdList></Reference><Reference><Citation>Piedra-Quintero ZL, et al. CD38: an immunomodulatory molecule in inflammation and autoimmunity. Front Immunol. 2020;11: 597959.</Citation><ArticleIdList><ArticleId IdType="pubmed">33329591</ArticleId><ArticleId IdType="pmc">7734206</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2020.597959</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Donk NW, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270(1):95&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">26864107</ArticleId><ArticleId IdType="pmc">4755228</ArticleId><ArticleId IdType="doi">10.1111/imr.12389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostendorf L, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. 2020;383(12):1149&#x2013;55.</Citation></Reference><Reference><Citation>Lokhorst HM, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">26308596</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1506348</ArticleId></ArticleIdList></Reference><Reference><Citation>Maixnerova D, et al. New treatment strategies for IgA nephropathy: targeting plasma cells as the main source of pathogenic antibodies. J Clin Med. 2022;11(10):2810.</Citation><ArticleIdList><ArticleId IdType="pubmed">35628935</ArticleId><ArticleId IdType="pmc">9147021</ArticleId><ArticleId IdType="doi">10.3390/jcm11102810</ArticleId></ArticleIdList></Reference><Reference><Citation>Basler M, et al. The immunoproteasome: a novel drug target for autoimmune diseases. Clin Exp Rheumatol. 2015;33(4 Suppl 92):S74&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26458097</ArticleId></ArticleIdList></Reference><Reference><Citation>Khodadadi L, et al. Bortezomib plus continuous B cell depletion results in sustained plasma cell depletion and amelioration of lupus nephritis in NZB/W F1 Mice. PLoS ONE. 2015;10(8): e0135081.</Citation><ArticleIdList><ArticleId IdType="pubmed">26252021</ArticleId><ArticleId IdType="pmc">4529137</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0135081</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, et al. The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. Lupus. 2017;26(9):952&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28059023</ArticleId><ArticleId IdType="doi">10.1177/0961203316686703</ArticleId></ArticleIdList></Reference><Reference><Citation>Segarra A, Arredondo KV. Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience. Lupus. 2020;29(2):118&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">31865857</ArticleId><ArticleId IdType="doi">10.1177/0961203319896018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk CJ, et al. Discovery and early clinical development of selective immunoproteasome inhibitors. Cells. 2021;11(1):9.</Citation><ArticleIdList><ArticleId IdType="pubmed">35011570</ArticleId><ArticleId IdType="pmc">8750005</ArticleId><ArticleId IdType="doi">10.3390/cells11010009</ArticleId></ArticleIdList></Reference><Reference><Citation>Lickliter J, et al. AB0509 Kzr-616, a selective inhibitor of the immunoproteasome, shows a promising safety and target inhibition profile in a phase i, double-blind, single (SAD) and multiple ascending dose (MAD) study in healthy volunteers. Ann Rheum Dis. 2018;77(Suppl 2):1413&#x2013;4.</Citation></Reference><Reference><Citation>Kale A, et al. Diabetes and cardiorenal complications: a clinical review of existing therapies and novel combinations, focusing on SGLT2 inhibitors. Curr Diabetes Rev. 2022. https://doi.org/10.2174/157339981966622081614590763 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157339981966622081614590763</ArticleId><ArticleId IdType="pubmed">35975848</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan P, et al. Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022;17(12):1730&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">36323444</ArticleId><ArticleId IdType="doi">10.2215/CJN.03790322</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakroush S, et al. Comparative analysis of SGLT-2 expression in renal vasculitis and lupus nephritis. Ann Rheum Dis. 2022;81(7):1048&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">35217513</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2022-222167</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, et al. Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial. RMD Open. 2022;8(2): e002686.</Citation><ArticleIdList><ArticleId IdType="pubmed">36288823</ArticleId><ArticleId IdType="pmc">9615980</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2022-002686</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuffield Department of Population Health Renal Studies Group, SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists&#x2019; Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788&#x2013;1801.</Citation></Reference><Reference><Citation>Herrington WG, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">36331190</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2204233</ArticleId></ArticleIdList></Reference><Reference><Citation>Sizar O, Podder V, Talati R. Empagliflozin. StatPearls. Treasure Island: StatPearls Publishing LLC. Copyright &#xa9; 2022.</Citation></Reference><Reference><Citation>Barrera-Chimal J, Jaisser F, Anders HJ. The mineralocorticoid receptor in chronic kidney disease. Br J Pharmacol. 2022;179(13):3152&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">34786690</ArticleId><ArticleId IdType="doi">10.1111/bph.15734</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakris GL et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. 2020;383(23):2219&#x2013;29.</Citation></Reference><Reference><Citation>Peleg Y, Bomback AS, Radhakrishnan J. The evolving role of calcineurin inhibitors in treating lupus nephritis. Clin J Am Soc Nephrol. 2020;15(7):1066&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">32152065</ArticleId><ArticleId IdType="pmc">7341791</ArticleId><ArticleId IdType="doi">10.2215/CJN.13761119</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo YA. Voclosporin: first approval. Drugs. 2021;81(5):605&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">33788181</ArticleId><ArticleId IdType="pmc">8010786</ArticleId><ArticleId IdType="doi">10.1007/s40265-021-01488-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">33971155</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(21)00578-X</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gelder T, Lerma E. Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis. Expert Rev Clin Pharmacol. 2022;15(5):515&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">35763288</ArticleId><ArticleId IdType="doi">10.1080/17512433.2022.2092470</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, et al. Glomerulonephritis: immunopathogenesis and immunotherapy. Nat Rev Immunol. 2023. https://doi.org/10.1038/s41577-022-00816-y .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00816-y</ArticleId><ArticleId IdType="pubmed">36635359</ArticleId><ArticleId IdType="pmc">9838307</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne DR, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">33596356</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2023386</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad N, et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet. 2022;400(10354):733&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">36041475</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)01349-6</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>